Organ-on-Chip Market - A Global and Regional Analysis: Focus on Offering, Organ Type, Application, End User, and Country - Analysis and Forecast, 2024-2033

The global organ-on-chip market is projected to reach $3,596.3 million by 2033 from $109.9 million in 2023, growing at a CAGR of 42.09% during the forecast period 2024-2033. The key factors driving the growth of the global organ-on-chip market include continuous technological advancements in the fields of drug discovery, toxicity testing, and microfluidics. The combination of tissue engineering, microfluidics, and cell biology has contributed to the development of a micro-engineered organ-on-chip (OOC) platform. Huge R&D investments and collaboration with government agencies and OOC players are further contributing to the market growth.

Market Introduction

The global organ-on-chip market consists of products and services products such as instrument systems, chips or microfluidic devices, consumables, and software and data analysis tools, as well as organ types that include liver-on-a-chip, kidney-on-a-chip, lung-on-a-chip, heart-on-a-chip, brain-on-a- chip, and other organ-on-chip.

Impact Analysis:

The organ-on-chip market has made an impact in the following ways:

Increasing Partnerships among Players: The organ-on-chip market has been witnessing a notable increase in partnerships among key players, driven by the need for advanced solutions in drug development and personalized medicine. Collaborative efforts have become more prevalent as companies aim to leverage each other's technological expertise and market presence. For instance, partnerships between pharmaceutical giants and biotech firms are facilitating the integration of innovative organ-on-chip technologies into mainstream drug testing processes. These alliances are not only enhancing research capabilities but also accelerating the commercialization of organ-on-chip platforms.

Increasing Investment and Funding for Organ-on-Chip Technologies: The organ-on-chip market has been experiencing a surge in investment and funding, reflecting growing confidence in the technology's potential to revolutionize drug development and personalized medicine. Venture capitalists, private equity firms, and large pharmaceutical companies are increasingly allocating substantial resources to support the development and commercialization of organ-on-chip platforms. This influx of capital is enabling startups and established players alike to accelerate their research and development efforts, expand their technological capabilities, and bring innovative solutions to the market more rapidly.

Market Segmentation:

Segmentation 1: by Application

• Drug Discovery
• Toxicity Testing
• Other Applications

Drug Discovery Segment to Continue Dominating the Organ-on-Chip Market (by Application)

Based on application, the organ-on-chip market has been led by drug discovery, which held a 65.20% share in 2023.

Segmentation 2: by Offering

• Product
• Services

Product Segment to Continue Dominating the Organ-on-Chip Market (by Offering)

Based on offering, the organ-on-chip market has been led by product, which held a 53.94% share in 2023.

Segmentation 3: by Organ Type

• Liver-on-a-Chip
• Kidney-on-a-Chip
• Lung-on-a-Chip
• Heart-on-a-Chip
• Brain-on-a-Chip
• Other Organ-on-Chip

Liver-on-a-Chip Segment to Continue Dominating the Organ-on-Chip Market (by Organ Type)

Based on organ type, the organ-on-chip market has been led by liver-on-a-chip, which held a 28.31% share in 2023.

Segmentation 4: by End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Cosmetic Industry
• Others

Pharmaceutical and Biotechnology Companies Segment to Continue Dominating the Organ-on-Chip Market (by End User)

Based on end user, the organ-on-chip market has been led by pharmaceutical and biotechnology companies, which held a 72.69% share in 2023.

Segmentation 5: by Region

• North America: U.S., and Canada
• Europe: U.K., Germany, France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific: China, Japan, India, South Korea, and Rest-of-Asia-Pacific
• Latin America
• Middle East and Africa

Rest-of- Asia-Pacific dominated the Asia-Pacific organ-on-chip market in 2023. This region includes fast-growing economies such as Indonesia and Thailand, where increased healthcare spending and governmental research support are beginning to foster market growth. Challenges across these markets include varying regulatory environments and sometimes limited local funding for high-tech research.

Recent Developments in the Organ-on-Chip Market

• In April 2024, CN Bio Innovations Ltd. secured $21 million in the initial closing of its Series B investment round.
• In April 2024, CN Bio Innovations Ltd. was chosen for the NC3R’s SensOoChip Challenge, tasked with developing advanced Heart-on-a-Chip technology.
• In January 2024, CN Bio Innovations Ltd. and Altis Biosystems joined forces to develop a human gut/liver in vitro model for advanced absorption, distribution, metabolism, and excretion (ADME) studies.
• In March 2024, InSphero's liver disease team released a groundbreaking peer-reviewed paper in Nature's Scientific Reports, pushing the boundaries of in vitro models in MASH Drug Discovery.

Demand - Drivers and Limitations

Market Demand Drivers:

Increasing Demand for Animal-Free Testing: The growing demand for animal-free testing methods has significantly advanced organ-on-chip technology. These systems, which replicate human organ functions in vitro, are revolutionizing biomedical research and pharmaceutical development. Their capability to mimic human physiology, coupled with long-term cost-efficiency and high-throughput screening, makes them essential tools in modern healthcare and drug discovery. Additionally, the customizable nature of organ-on-chip systems and their alignment with ethical and sustainable practices are expected to further drive innovation and adoption across various research domains.

Increasing Focus on Organ-on-Chip Technology: Organ-on-chip technology has been experiencing a surge in emphasis due to several factors. Ethical concerns surrounding animal testing are driving the search for alternatives, while the potential for improved accuracy in drug development compared to animal models is highly attractive. Additionally, organ-on-chip systems offer potential cost-effectiveness and faster drug discovery through the ability to test multiple compounds simultaneously.

Rising Adoption of Organ-on-Chip (OOC) Technology among Pharmaceutical and Biotechnology Companies: Pharmaceutical and biotechnology companies are increasingly adopting organ-on-chip (OOC) technology due to its transformative potential in drug development and biomedical research. These microfluidic platforms replicate human organ structure and function, providing a more physiologically relevant environment for studying disease mechanisms, drug responses, and toxicity. The growing adoption of OOC technology has been driven by several key factors.

Firstly, OOC platforms offer a more accurate and predictive model compared to traditional cell cultures or animal studies. This enhanced fidelity improves the reliability of preclinical testing, enabling more informed decision-making during drug development. Additionally, OOC systems present a cost-effective alternative to animal studies, reducing the time and resources needed for preclinical research.

Secondly, OOC technology supports high-throughput screening of drug candidates, allowing companies to simultaneously assess multiple compounds in a controlled microenvironment. This capability accelerates the drug discovery process and aids in identifying promising candidates for further development.

Market Challenges:

Limitation of Use Restricted to Preclinical Trials: The use of organ-on-chip (OOC) technology is currently limited primarily to preclinical trials, which could pose a significant constraint on its broader application in clinical settings. While OOC platforms offer remarkable advantages in mimicking human physiology and predicting drug responses, their use is restricted by regulatory and validation challenges. These technologies are yet to be fully integrated into clinical trial phases, as extensive validation and standardization are required to ensure their reliability and reproducibility in a clinical context.

Difficulty in Mimicking Complex Tissues and Organs: One of the significant challenges faced by organ-on-chip (OOC) technology is the difficulty in accurately mimicking complex tissues and organs. While OOC platforms have made impressive strides in replicating simpler organ functions, reproducing the intricate architecture and multifaceted interactions of complex tissues remains a formidable task. The limitations in current microfabrication techniques and biomaterials might hinder the development of fully functional models that precisely emulate the dynamic environment of human organs. Additionally, achieving the integration of multiple cell types and ensuring their long-term viability and functionality within the chip adds another layer of complexity.

Market Opportunities:

Development of Multi-Organ-on-Chip Systems: The development of multi-organ-on-chip (OOC) systems marks a significant stride in biomedical research and drug development. These systems integrate various organ-on-chip platforms into a unified device, enabling researchers to replicate the intricate interactions between different organs and study complex physiological responses more comprehensively. By simulating the interconnectedness and communication between organs, multi-organ-on-chip systems offer a more realistic model of human biology than single-organ models.

Organ-on-Chip Technologies to Hasten Transition to Personalized Medicine: Organ-on-chip (OOC) technologies represent a transformative approach in biomedical research that is expected to hasten the transition to personalized medicine. These innovative platforms replicate the microenvironments and functionalities of human organs, allowing for the study of organ-level responses in a controlled setting. By incorporating patient-derived cells or tissues into OOC models, researchers can assess individualized responses to treatments and therapies, paving the way for tailored healthcare solutions. OOC technologies offer several advantages for personalized medicine, including the ability to mimic disease states, evaluate drug efficacy and toxicity with higher accuracy, and optimize treatment strategies based on patient-specific characteristics. Furthermore, OOC platforms enable researchers to explore complex disease mechanisms, identify biomarkers, and develop targeted therapies for precision medicine approaches. As these technologies continue to evolve and gain traction, they hold immense potential to revolutionize healthcare by providing more effective, efficient, and patient-centered solutions.

How can this report add value to an organization?

Product/Innovation Strategy: The global organ-on-chip market has been extensively segmented based on various categories, such as technology, products, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and collaborations accounted for the maximum number of key developments, i.e., nearly 30.77% of the total developments in the global organ-on-chip market were between January 2021 and April 2024.

Competitive Strategy: The global organ-on-chip market has numerous established players with product portfolios. Key players in the global organ-on-chip market analyzed and profiled in the study involve established players offering organ-on-chip.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Detailed secondary research was performed to ensure maximum coverage of manufacturers/suppliers operational in a country.
• Exact revenue information, up to a certain extent, was extracted for each company from secondary sources and databases. The revenues specific to the application, offering, organ type, and region were then estimated for each market player based on fact-based proxy indicators as well as primary inputs.
• The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study on organ-on-chip.
• The market contribution of the organ-on-chip products anticipated to be launched in the future has been calculated based on historical analysis. This analysis has been supported by proxy factors such as the innovation scale of the companies, the status of funding, collaborations, customer base, and patent scenario.
• The scope of availability of organ-on-chip products and technologies in a particular region has been assessed based on a comprehensive analysis of companies’ prospects, regional end-user perception, and other factors impacting the launch of organ-on-chip in that region.
• The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2021-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033.
• Revenues of the companies have been referenced from their annual reports for FY2020-FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, product approval status, market collaborations, and operational history.
• Regional distribution of the market revenue has been estimated based on the companies in each region and the adoption rate of organ-on-chip. All the numbers have been adjusted to a single digit after the decimal for better presentation in the report. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the period 2024-2033.
• The market has been mapped based on the available organ-on-chip offerings. All the key companies with significant offerings in this field have been considered and profiled in this report.
• Market strategies and developments of key players have been considered for the calculation of the potential of the market in the forecast period.

Primary Research:

The primary sources involve industry experts in the organ-on-chip market, including the market players offering organ-on-chip products. Resources such as CXOs, vice presidents, product managers, directors, territory managers, and business development have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report’s segmentation and key qualitative findings for organ-on-chip
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Validation of the numbers of the different segments of the market in focus
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• European Medicines Agency (EMA), Food and Drug Administration (FDA), Frontiers, World Health Organization (WHO), National Center for Advancing Translational Sciences (NCATS), and National Center for Biotechnology Information (NCBI), among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolios
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentation and percentage share estimates
• Companies’ and countries’ understanding and data for market value estimation
• Key industry/market trends
• Developments among top players
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, type portfolio, and market penetration.

Some prominent names in the global organ-on-chip market include:

• Emulate, Inc.
• Mimetas B.V.
• Kirkstall Ltd.
• Numa Biosciences
• AxoSim
• BICO Group AB
• CN Bio Innovations Ltd.
• TissUse GmbH
• InSphero
• The Charles Stark Draper Laboratory, Inc.
• Obatala Sciences

This product will be delivered within 3-5 business days.